KRAS mutations in solid tumors appear in 90% of pancreatic cancer cases, 10%–15% of lung cancer (mainly NSCLC) cases, and 30%–40% of colorectal cancer cases. This evidence concerns the gene KRAS and familial pancreatic carcinoma.